GlassScriptPhysician profile
Sivakumar Nagaraju
NPI 1952373235
$4,768.09
in general payments reported to CMS, 2019-2025
33 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $95.75 · 2021: $12.48 · 2022: $591 · 2023: $1,171 · 2024: $1,168 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,412.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,203.71 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $693.12 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.22 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Grifols USA, LLC | $356.00 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $282.65 | 2022-2025 | Dupixent |
| Mylan Specialty L.P. | $211.76 | 2019-2024 | Yupelri |
| Intuitive Surgical, INC. | $169.86 | 2024 | |
| Abbvie INC. | $136.21 | 2022-2025 | |
| Genzyme Corporation | $134.90 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $125.02 | 2023-2024 | Xywav |
| Abiomed | $107.96 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.86 | 2023-2024 | Glassia |
| Actelion Pharmaceuticals US, INC. | $94.07 | 2023-2025 | Opsumit, Uptravi |
| Pfizer INC. | $89.29 | 2022-2025 | |
| Viatris Specialty LLC | $80.95 | 2025 | Yupelri |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $77.26 | 2019-2025 | |
| Genentech USA, INC. | $74.26 | 2019-2022 | |
| Amgen INC. | $57.44 | 2023-2025 | Tezspire |
| Allergan, INC. | $43.92 | 2019 | |
| Insmed, INC. | $42.46 | 2025 | Brinsupri, Arikayce |
| Lilly USA, LLC | $42.22 | 2023-2025 | Mounjaro |
| Itamar Medical INC | $32.37 | 2025 | Watchpatone |
| Ethicon INC. | $31.78 | 2022 | |
| La Jolla Pharmaceutical Company | $30.98 | 2025 | Zevtera |
| Baxter Healthcare | $28.69 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Shire North American Group INC | $28.35 | 2019 | |
| Gilead Sciences, INC. | $23.14 | 2022 | |
| Tactile Systems Technology INC | $18.86 | 2024 | Flexitouch Plus, Entre Plus |
| United Therapeutics Corporation | $18.21 | 2022 | |
| Philips North America LLC | $18.14 | 2022 | |
| Ani Pharmaceuticals, INC. | $14.54 | 2023 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $12.87 | 2019 | |
| Circassia INC. | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sivakumar Nagaraju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.